EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

DNA-PK inhibition enhances neoantigen diversity and increases T cell responses to immunoresistant tumors

Allison J Nielsen, Gabriella K Albert, Amelia Sanchez, Jiangli Chen, Jing Liu, Andres S Davalos, Degui Geng, Xander Bradeen, Jennifer D Hintzsche, William Robinson, Martin McCarter, Carol Amato und 4 weitere

Journal of Clinical Investigation · 2024

DOI: 10.1172/jci180278 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2024. Verfasst von Allison J Nielsen und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Medical Oncology, University of Colorado School of Medicine, Aurora, Colorado, USA. Hauptthemen laut MEDLINE: DNA-Activated Protein Kinase, Antigens, Neoplasm, Melanoma. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: BLRD VA, NCI NIH HHS, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Effective antitumor T cell activity relies on the expression and MHC presentation of tumor neoantigens. Tumor cells can evade T cell detection by silencing the transcription of antigens or by altering MHC machinery, resulting in inadequate neoantigen-specific T cell activation. We identified the DNA–protein kinase inhibitor (DNA-PKi) NU7441 as a promising immunomodulator that reduced immunosuppressive proteins, while increasing MHC-I expression in a panel of human melanoma cell lines. In tumor-bearing mice, combination therapy using NU7441 and the immune adjuvants stimulator of IFN genes (STING) ligand and the CD40 agonist NU-SL40 substantially increased and diversified the neoantigen landscape, antigen-presenting machinery, and, consequently, substantially increased both the number and repertoire of neoantigen-reactive, tumor-infiltrating lymphocytes (TILs). DNA-PK inhibition or KO promoted transcription and protein expression of various neoantigens in human and mouse melanomas and induced sensitivity to immune checkpoint blockade (ICB) in resistant tumors. In patients, protein kinase, DNA-activated catalytic subunit ( PRKDC ) transcript levels were inversely correlated with MHC-I expression and CD8 + TILs but positively correlated with increased neoantigen loads and improved responses to ICB. These studies suggest that inhibition of DNA-PK activity can restore tumor immunogenicity by increasing neoantigen expression and presentation and broadening the neoantigen-reactive T cell population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DNA-Activated Protein KinaseAntigens, NeoplasmMelanomaAnimalsHumansMiceCell Line, TumorMorpholinesLymphocytes, Tumor-InfiltratingProtein Kinase InhibitorsMice, KnockoutNeoplasm ProteinsT-LymphocytesChromonesDNA-Binding Proteins

Stichwörter der Autor:innen

Adaptive immunityAntigen presentationCancer immunotherapyImmunologyOncology

Substanzen

DNA-Activated Protein KinaseAntigens, NeoplasmMorpholines8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-onePRKDC protein, humanPrkdc protein, mouseProtein Kinase InhibitorsNeoplasm ProteinsChromonesDNA-Binding Proteins

Autor:innen und Institutionen

  • Department of Medicine, Division of Medical Oncology, University of Colorado School of Medicine, Aurora, Colorado, USA.
  • Department of Veterans Affairs, Research Service, Rocky Mountain Regional Veterans Affairs, Aurora, Colorado, USA.
  • PherDal Science, Dixon, Illinois, USA.
  • University of Colorado Comprehensive Cancer Center and.
  • Department of Surgery, University of Colorado School of Medicine, Aurora, Colorado, USA.

Förderung

  • BLRD VA
  • NCI NIH HHS
  • National Cancer Institute
  • Department of Veteran Affairs

Zitieren

APA

Nielsen, A. J., Albert, G. K., Sanchez, A., Chen, J., Liu, J., Davalos, A. S., Geng, D., Bradeen, X., Hintzsche, J. D., Robinson, W., McCarter, M., Amato, C., Tobin, R., Couts, K., Wilky, B. A., & Davila, E. (2024). DNA-PK inhibition enhances neoantigen diversity and increases T cell responses to immunoresistant tumors. Journal of Clinical Investigation. https://doi.org/10.1172/jci180278

Vancouver

Nielsen AJ, Albert GK, Sanchez A, Chen J, Liu J, Davalos AS, et al. DNA-PK inhibition enhances neoantigen diversity and increases T cell responses to immunoresistant tumors. Journal of Clinical Investigation. 2024. doi:10.1172/jci180278

BibTeX
@article{Nielsen2024,
  author = {Nielsen, Allison J and Albert, Gabriella K and Sanchez, Amelia and Chen, Jiangli and Liu, Jing and Davalos, Andres S and Geng, Degui and Bradeen, Xander and Hintzsche, Jennifer D and Robinson, William and McCarter, Martin and Amato, Carol and Tobin, Richard and Couts, Kasey and Wilky, Breelyn A and Davila, Eduardo},
  title = {DNA-PK inhibition enhances neoantigen diversity and increases T cell responses to immunoresistant tumors},
  journal = {Journal of Clinical Investigation},
  year = {2024},
  doi = {10.1172/jci180278}
}
Kostenlos starten →